Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, Jan. 31 '26)

Image
By G.M.

 


    Clin Infect Dis

  1. BRAMANTE CT, Boulware DR
    Preventing Long COVID With Metformin.
    Clin Infect Dis. 2026 Jan 29:ciaf700. doi: 10.1093.
    PubMed        


    Emerg Infect Dis

  2. PERERA RAPM, Marques A, Graham-Wooten J, Tan LH, et al
    Enhanced Isolation and Detection of COVID-19 in Hospitalized Patients Undergoing Antiviral Therapy.
    Emerg Infect Dis. 2026;32:103-113.
    PubMed         Abstract available


    Graefes Arch Clin Exp Ophthalmol

  3. NEO YN, Martinez-Alvarez L, Davagnanam I, Girafa G, et al
    Correction: Treatment of post-vaccination optic neuritis: implications from the global SARS-CoV-2 vaccination effort.
    Graefes Arch Clin Exp Ophthalmol. 2026 Jan 29. doi: 10.1007/s00417-026-07129.
    PubMed        


    Int J Infect Dis

  4. NGIAM JN, Wee LE, Lim JT, Loy EX, et al
    Early administration of neutralising monoclonal antibodies and post-acute sequelae of COVID-19.
    Int J Infect Dis. 2026 Jan 25:108435. doi: 10.1016/j.ijid.2026.108435.
    PubMed         Abstract available

  5. LAI ZL, Su YD, Hsu YY, Hung YH, et al
    An integrative viro-bacterial signature based on viral load and high-resolution microbiome profiling predicts COVID-19 mortality.
    Int J Infect Dis. 2025;161:108153.
    PubMed         Abstract available

  6. SHEN Y, Shahn Z, Robertson MM, Gebo K, et al
    Natural History of Self-reported Symptoms Following SARS-CoV-2 Infection: A Target Trial Emulation in a Prospective Community-recruited Cohort.
    Int J Infect Dis. 2026 Jan 23:108422. doi: 10.1016/j.ijid.2026.108422.
    PubMed         Abstract available

  7. HAKIM S, Haque MA
    Health system capacity for infectious disease pandemic response in low- and lower-middle-income countries: Insights from national health facility surveys.
    Int J Infect Dis. 2026;163:108281.
    PubMed         Abstract available


    J Med Virol

  8. HAN Z, Han J, Zhao Y, Xu C, et al
    Research Progress of Coronavirus Reverse Genetics Technology.
    J Med Virol. 2026;98:e70792.
    PubMed         Abstract available

  9. HORTON M, Smith AB, Milne R, Winch D, et al
    Large-Scale Psychometric Assessment and Validation of the Modified COVID-19 Yorkshire Rehabilitation Scale Patient-Reported Outcome Measure for Long COVID or Post-COVID Syndrome.
    J Med Virol. 2026;98:e70816.
    PubMed         Abstract available

  10. LA ROCCA V, Filipponi C, Diesendorf V, De Carli A, et al
    N-Acylethanolamine Acid Amidase Inhibition Reduces SARS-CoV-2 Infection in Human Precision Cut-Lung Slices and Downregulates NF-KBB Signalling.
    J Med Virol. 2026;98:e70819.
    PubMed         Abstract available


    Radiology

  11. SPOSATO A, Mazzola MA, Kunst MM
    Case 346.
    Radiology. 2026;318:e251975.
    PubMed         Abstract available


    Travel Med Infect Dis

  12. HUANG SH, Lin YC, Shih YL, Kuo JS, et al
    Impact of the COVID-19 Pandemic on Travel Medicine Services in Taiwan, 2019-2022.
    Travel Med Infect Dis. 2026 Jan 22:102956. doi: 10.1016/j.tmaid.2026.102956.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »